When was Mesa Verde Venture Partners founded?

Mesa Verde Venture Partners was founded in 2006.

Where is Mesa Verde Venture Partners' headquarters located?

Mesa Verde Venture Partners' headquarters is located in San Diego ( United States ).

How big is Mesa Verde Venture Partners' investment team?

Mesa Verde Venture Partners has a team of 9, including 3 partners.

How many companies has Mesa Verde Venture Partners invested in?

Mesa Verde Venture Partners has invested in 21 companies, including CalciMedica & Immusoft.

Which companies has Mesa Verde Venture Partners invested in lately?

Immusoft & CalciMedica are the latest investments by Mesa Verde Venture Partners.

What sectors does Mesa Verde Venture Partners focus on for investments?

Top sectors in Mesa Verde Venture Partners' portfolio are Life Sciences (17 investments) and High Tech (7 investments).

What stages of companies does Mesa Verde Venture Partners typically invest in?

Mesa Verde Venture Partners primarily invests in Series B and Series A stages.

Mesa Verde Venture Partners - 2025 Investor Profile, Portfolio, Team & Investment Trends - Tracxn

Q: How many exits has Mesa Verde Venture Partners been involved in?

Mesa Verde Venture Partners' portfolio has seen 4 IPOs and 8 acquisitions.

Mesa Verde Venture Partners is a venture capital firm founded in 2006. It is primarily based out of San Diego, United States. As of Mar 2021, Mesa Verde Venture Partners has invested in 21 companies. It primarily invests in Series B round in United States based startups. Its investments are spread across a wide range of sectors from Life Sciences to High Tech and Enterprise Applications. Most recently it led the $10.3M Series B round of Immusoft along with Ikarian Capital. This round also saw participation from Breakout Ventures.

Overall, Mesa Verde Venture Partners portfolio has seen 4 IPOs and 8 acquisitions including key companies like CalciMedica, Alastin Skincare and Exagen. A lot of funds co-invest with Mesa Verde Venture Partners, with names like Valence Life Sciences sharing a substantial percentage of its portfolio.

Mesa Verde Venture Partners has team of 9 people including 3 partners.

Key Metrics

Team Members

Carey Ng, Fred Middleton & 7 more

Portfolio Count

CalciMedica, Immusoft & 19 more

Portfolio Sectors

Life Sciences, High Tech & 4 more

Portfolio Locations

United States

Rounds of Entry

Series B, Series A & 2 more

Portfolio IPOs

Immix Biopharma, CalciMedica & 2 more

Portfolio Acquisitions

Satiogen, Alastin Skincare & 6 more

Portfolio Soonicorns

Glycomine

Mesa Verde Venture Partners has a portfolio of 21 companies. Their most notable investments are in Lineagen and Immusoft.Their portfolio spans across and United States. They have invested in Life Sciences, High Tech, Enterprise Applications and 3 other sectors, across stages such as Series B, Series A and 2 more. Here is the list of top investments by Mesa Verde Venture Partners:

1. CalciMedica

Developer of CRAC channel inhibitor drugs for inflammatory diseases. The Company has a portfolio of highly selective CRAC channel inhibitor drugs that it is developing to improve outcomes for patients with acute inflammatory indications.

Key facts about CalciMedica

Founded Year: 2006
Location: San Diego (United States)
Stage: Public
Total Funding till date: $76.7M
Employee Count: 11 as on Dec 31, 2022
Investors: Orbimed, SR One and 10 Others
Latest Funding Round: Conventional Debt, Apr 06, 2025, $32.5M
Highlight: Public

2. Immusoft

Immusoft develops autologous cell therapies based on its Immune system programming (ISP) technology. ISP approach enables in vivo delivery of gene-encoded medicines (biologics), by reprogramming the patient’s own B cells to replace missing or defective enzymes/proteins. It is using its technology in several therapeutic areas including enzyme/protein replacement, infectious disease, regenerative medicine, and cardiovascular disease. Immusoft seeks to enter collaborations or partnerships to develop the treatment in key indications including hemophilia, sarcopenia (muscle loss), and atherosclerosis. Its lead indication is MPS I Mucopolysaccharidosis Type I (MPS I), a lethal disease which results from the lack of a functional enzyme called α-L-iduronidase (IDUA).

Key facts about Immusoft

Founded Year: 2009
Location: Seattle (United States)
Stage: Series B
Total Funding till date: $44.1M
Investors: Mesa Verde Venture Partners, Alexandria and 23 Others
Latest Funding Round: Series B, May 28, 2024, $4.58M
Highlight: Editors' Pick

3. Alastin Skincare

ALASTIN Skincare is a brand of skin care products. Offers a range of products such as moisturizers, cleansers, balms, sunscreens, etc. The products are available in the US via its online store. The firm also sells products via partnered retail stores.

Key facts about Alastin Skincare

Founded Year: 2015
Location: Carlsbad (United States)
Stage: Acquired
Total Funding till date: $31.4M
Employee Count: 117 as on Dec 31, 2022
Investors: Mesa Verde Venture Partners, The Cambria Group and 4 Others
Latest Funding Round: Series A, May 08, 2019, $9.88M
Highlight: Acquired

4. Glycomine

Provider of replacement therapies for rare genetic diseases. The company is also developing nanocarriers to deliver proteins into affected cells and tissues. Its drug pipeline includes M1P substrate replacement therapy for Congenital Disorder of Glycosylation (CDG-Ia) and rhNgly1 enzyme replacement therapy for NGLY1 deficiency (or N-glycanase deficiency).

Key facts about Glycomine

Founded Year: 2015
Location: San Francisco (United States)
Stage: Series C
Total Funding till date: $195M
Investors: Abingworth, Novo Holdings and 16 Others
Latest Funding Round: Series C, Apr 16, 2025, $115M
Highlight: Editors' Pick

5. Exagen

Developer of diagnosis, prognosis, and monitoring solutions for autoimmune connective diseases. The products include Avise CTD is an autoimmune Connective Tissue Disease (CTD) diagnostic that helps physicians in the differential diagnosis of RA, Lupus, Fibromyalgia, Sjogren's, Scleroderma, PM/DM, APS, and Autoimmune Thyroid disease by using CB-CAPs (Cell-Bound Complement Activation Products) technology. Avise SLE Prognostic is a 10-biomarker panel to help assess a patient’s potential risk for Thrombosis, Cardiovascular events, Lupus Nephritis, and Neuropsychiatric Lupus. Avise Adalimumab and Avise Infliximab enable physicians to monitor drug level activity and neutralize anti-drug antibodies, thus optimizing patient treatment. Avise MTX measures active methotrexate (MTXPGs) to help physicians assess their patients' MTX dose; exposure. Avise HCQ is a drug monitoring test that provides a measurement of HCQ (Hydroxychloroquine) levels in whole blood to help physicians assess their patients' compliance and exposure to HCQ therapy. Avise Lupus is a diagnostic tool that helps physicians detect difficult-to-diagnose lupus.

Key facts about Exagen

Founded Year: 2002
Location: Vista (United States)
Annual Revenue: $45.6M as on Dec 31, 2022
Stage: Public
Total Funding till date: $110M
Employee Count: 204 as on Dec 31, 2022
Investors: CRG, Tullis Health Investors and 10 Others
Latest Funding Round: Series C, Jul 16, 2019, $22.6M
Highlight: Public

Want to see the entire list?

Mesa Verde Venture Partners has invested in 21 companies over the last 17 years, with an average of 1 new investment annually in the last 10 years. Its most recent first time investment was in CalciMedica and most recent follow-on round was in Immusoft.

Here are Mesa Verde Venture Partners' Year-on-Year Investment Trends:

Year	No. of Investments
Year	1^st Round	Follow-on	Total
2025 (YTD)	0	0	0
2024	0	0	0
2023	0	0	0
2022	0	0	0
2021	0	1	1
2020	1	0	1
2019	2	1	3
2018	1	0	1
2017	1	0	1

View all investments by Mesa Verde Venture Partners

Get Mesa Verde Venture Partners' portfolio delivered to your inbox!

Mesa Verde Venture Partners has made 4 investments in Series B stage with an average round size of $9.79M, 3 investments in Series A stage with an average round size of $13.8M, 2 investments in Seed stage with an average round size of $2.75M and 2 investments in Series C stage with an average round size of $11.3M.

Here are Mesa Verde Venture Partners' investments by stage:

Note: We have considered here, only first round of investments

Stage of entry	No. of Investments
Series B	4
Series A	3
Seed	2
Series C	2

View all investments by Mesa Verde Venture Partners

Mesa Verde Venture Partners has a diverse portfolio, with companies operating in the Life Sciences, High Tech, Healthcare and Sustainability Tech. Notably, it has invested in 15 Tech companies, 13 Enterprise (B2B) companies, 3 Consumer (B2C) companies and at least 2 companies focusing on Software.

Here are Mesa Verde Venture Partners' investments by sector:

Note: We have considered here, only first round of investments

Sector	No. of Investments
Life Sciences	10
High Tech	3
Healthcare	1
Sustainability Tech	1

View all investments by Mesa Verde Venture Partners

Mesa Verde Venture Partners has made most investments in United States (11).

View all investments by Mesa Verde Venture Partners

Mesa Verde Venture Partners has not made any investment in 2025 so far.

Here are the most recent investments by Mesa Verde Venture Partners:

Date	Company	Location	Round Details	Round Amount	Co-Investors
Mar 02, 2021	Immusoft	United States	Series B	$10.3M	Ikarian Capital [+1]
May 26, 2020	CalciMedica	United States	Series C	$17.2M	Valence Life Sciences [+2]
Jun 19, 2019	NeuraLace Medical	United States	Seed	$3.85M	Teal Ventures [+2]
May 20, 2019	Paradigm Dx	United States	Series B	Undisclosed	New Science Ventures [+5]
Jan 03, 2019	Immusoft	United States	Series B	$20.2M	600 Mile Challenge Fund [+5]

Get the detailed list of all investments by Mesa Verde Venture Partners. Download now!

See more recent investments made by Mesa Verde Venture Partners

4 of Mesa Verde Venture Partners' portfolio companies have become public. Immix Biopharma got listed on the National Association of Securities Dealers Automated Quotations (NASDAQ), in Dec 2021 at marketcap of $37.9M and CalciMedica got listed on the National Association of Securities Dealers Automated Quotations (NASDAQ).

Here are Mesa Verde Venture Partners' portfolio companies that went public:

Company	IPO Date	First Invested on	First Round of Investment	Round Size
Immix Biopharma	Dec 16, 2021	-	-	-
CalciMedica	Sep 25, 2020	May 26, 2020	Series C	$17.2M
Exagen	Sep 19, 2019	Sep 11, 2012	Series C	$5.31M
Oncternal Therapeutics	Feb 06, 2004	-	-	-

View more details about public companies in Mesa Verde Venture Partners' portfolio

8 companies from Mesa Verde Venture Partners' portfolio have been acquired. The most recent acquisition were Satiogen in May 2022 by Mirum Pharmaceuticals.

Here are Mesa Verde Venture Partners' portfolio companies that got acquired most recently:

Company	Acquisition Date	First Invested on	First Round of Investment	Round Size
Satiogen	May 23, 2022	Apr 15, 2008	Series A	$700K
Alastin Skincare	Nov 29, 2021	-	-	-
Lineagen	Aug 24, 2020	Aug 30, 2010	Series A	$10.8M
Paradigm Dx	Mar 03, 2020	Nov 30, 2018	Series B	$11M
Biomatrica	Oct 18, 2018	-	-	-

View all acquired companies in Mesa Verde Venture Partners' portfolio

Mesa Verde Venture Partners has a team of 9 members including 3 Partners and 3 Venture Partners located in United States. Mesa Verde Venture Partners' team does not sit on the board of any company as of now.

Here is a list of all team members in Mesa Verde Venture Partners:

Name	Designation	Location	Board Memberships	Contact details
Carey Ng	Partner	San Diego	-	1 Email
Fred Middleton	Partner	Burlingame	-	2 Emails
Francois Ferre	Partner	San Diego	-	1 Email
David Mallery	Venture Partner	San Diego	-	-
Duwaine Townsen	Venture Partner	San Diego	-	-
Cam Gallagher	Venture Partner	Scottsdale	-	-
Randy Berholtz	Advisor	San Diego	-	3 Emails, 1 Phone number
Magda Marquet	Advisor	San Diego	-	1 Email
Ray McKewon	Advisor	Rancho Santa Fe	-	-

Get the full list of Mesa Verde Venture Partners' team & partners for free. Download now!

View team details of Mesa Verde Venture Partners

Over the past 17 years, 61 investors have co-invested in Mesa Verde Venture Partners's portfolio companies.

Invested before Mesa Verde Venture Partners: HHS, Sanderling Ventures and 13 others have invested in rounds before Mesa Verde Venture Partners. There are 2 companies where HHS has invested before Mesa Verde Venture Partners and 1 company where Sanderling Ventures has invested before Mesa Verde Venture Partners.
Top Co-investors of Mesa Verde Venture Partners: 21 investors entered a company along with Mesa Verde Venture Partners. These include investors like Valence Life Sciences (1 company).
Invested after Mesa Verde Venture Partners: A total of 25 investors have invested in Mesa Verde Venture Partners's portfolio after their investments. Top Investors include Avenue Capital Group (1 company), State of California (1 company) and Ikarian Capital (1 company).